Scancell Limited - Company & Market Research Reports

Scancell was founded in 1996 and is headquartered in Nottingham, United Kingdom. Scancell main 2 cancer vaccine programmes are ImmunoBody® and Moditope®. Scancells first vaccine SCIB1 is showing positive results for patients in resected Stage II or III disease, it is used to treat melanoma. Scancell Limited operates as a subsidiary of Scancell Holdings PLC.

From
From
From
From
Gastric Cancer - Pipeline Review, H2 2018 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H2 2018

  • Drug Pipelines
  • 1462 Pages
From
Esophageal Cancer - Pipeline Review, H2 2018 - Product Thumbnail Image

Esophageal Cancer - Pipeline Review, H2 2018

  • Drug Pipelines
  • 779 Pages
From
Osteosarcoma - Pipeline Review, H2 2018 - Product Thumbnail Image

Osteosarcoma - Pipeline Review, H2 2018

  • Drug Pipelines
  • 498 Pages
From
Osteosarcoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Osteosarcoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 421 Pages
From
Gastric Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1283 Pages
From
From
From
Pancreatic Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2509 Pages
From
Ovarian Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2412 Pages
From
Colorectal Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Colorectal Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2237 Pages
From
From
Melanoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Melanoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2011 Pages
From
From
Loading Indicator
adroll